Abbvie Inc
NYSE:ABBV
Abbvie Inc
Income from Continuing Operations
Abbvie Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$5.6B
|
CAGR 3-Years
298%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
Seagen Inc
NASDAQ:SGEN
|
Income from Continuing Operations
-$750.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-29%
|
See Also
What is Abbvie Inc's Income from Continuing Operations?
Income from Continuing Operations
4.9B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Income from Continuing Operations amounts to 4.9B USD.
What is Abbvie Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
2%
Over the last year, the Income from Continuing Operations growth was -59%. The average annual Income from Continuing Operations growth rates for Abbvie Inc have been 2% over the past three years , -3% over the past five years , and 2% over the past ten years .